DoW Toxic Exposures Translational Research Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The FY26 Toxic Exposures Research Program (TERP) Translational Research Award aims to support research that bridges basic science and clinical applications related to military-related toxic exposures. The focus is on accelerating the development of healthcare products, interventions, technologies, or clinical practice guidelines by promoting integrative research that facilitates the bidirectional transfer of knowledge between foundational science and clinical observations. Applications may incorporate New Approach Methodologies and are expected to demonstrate a strong connection between basic and clinical elements within their research plans. A notable feature of this award is the Partnering Principal Investigator Option (PPIO), which encourages interdisciplinary collaboration by allowing the designation of an initiating PI alongside a Partnering PI. If funded, each investigator receives separate awards, fostering partnerships that can significantly enhance research outcomes beyond individual efforts. This structure is designed to promote teamwork, particularly between clinicians and research scientists, to expedite translating promising ideas into clinical use. The program is overseen by the Department of the Army through the Department of Defense and was announced in early May 2026.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan.
Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP TRA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising ideas into clinical applications. Partnering should significantly advance the research beyond what would be possible through individual efforts.
